Clinical Problem Solving

Cooley, Christine L.; Nishino, Mizuki; Jagannathan, Jyothi P.; Ramaiya, Nikhil H.; Salvo, Donald Di; Krajewski, Katherine M.

doi:10.7863/ultra.33.1.9

Cited by 3 publications

(1 citation statement)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, in the case of SERM or tamoxifen use, proestrogenic effects are observed in the uterus, including benign entities (endometrial polyps, hyperplasia, adenomyosis, and fibroids) and malignant disease (endometrial carcinoma, and sarcoma) (88). Tamoxifen use is also associated with hepatic steatosis.…”

Section: Non-anti-angiogenic Molecular Targeted Therapiesmentioning

confidence: 99%

Molecular Targeted Therapy in Modern Oncology: Imaging Assessment of Treatment Response and Toxicities

et al. 2017

Self Cite

View full text Add to dashboard Cite

Oncology is a rapidly evolving field with a shift toward personalized cancer treatment. The use of therapies targeted to the molecular features of individual tumors and the tumor microenvironment has become much more common. In this review, anti-angiogenic and other molecular targeted therapies are discussed, with a focus on typical and atypical response patterns and imaging manifestations of drug toxicities.

show abstract

Section: Non-anti-angiogenic Molecular Targeted Therapiesmentioning

confidence: 99%

Molecular Targeted Therapy in Modern Oncology: Imaging Assessment of Treatment Response and Toxicities

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

Biliary and pancreatic complications of molecular targeted therapies in cancer imaging

et al. 2017

View full text Add to dashboard Cite

The purpose of this review is to familiarize radiologists with the different imaging manifestations of biliary and pancreatic toxicity of molecular targeted therapies. The advent of molecular targeted therapies for cancer treatment has prompted radiologists to be familiar with these new molecules, their patterns of response, and their class-specific toxicities. While liver and bowel toxicities have been extensively reported in literature, less is known about the pathogenesis and imaging of toxicity involving the pancreatobiliary system. Biliary and pancreatic toxicity of molecular targeted therapies present with variable manifestations and varying degrees of severity, from asymptomatic liver function tests elevation to acute pancreatitis or cholecystitis. Management of these conditions depends on the clinical scenario and the severity of the findings. In this article, we will (1) present the various classes of molecular targeted therapies most commonly associated with biliary and pancreatic toxicity; (2) illustrate imaging findings of drug-associated biliary and pancreatic injuries and their possible differential diagnosis; and (3) provide a guide for management of these conditions.

show abstract

Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors

et al. 2017

View full text Add to dashboard Cite

Clinical Problem Solving

Cited by 3 publications

References 52 publications

Molecular Targeted Therapy in Modern Oncology: Imaging Assessment of Treatment Response and Toxicities

Molecular Targeted Therapy in Modern Oncology: Imaging Assessment of Treatment Response and Toxicities

Biliary and pancreatic complications of molecular targeted therapies in cancer imaging

Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors

Contact Info

Product

Resources

About